US weighs allowing most pharma licensing deals with China, sources say

Major drugmakers including Pfizer have met in recent months with Trump administration officials, including Treasury Secretary Scott Bessent. They have argued against broad restrictions on investments tied to Chinese drug development, saying they could cut US companies off from a fast-growing source of new medicines, the sources said. Pfizer CEO Albert Bourla said in an interview that he had discussed China and national security concerns with Bessent, Secretary of State Marco Rubio and representatives of the US Department of Health and Human Services. Bourla said he does not believe US drugmakers signing deals to license medicines from Chinese companies creates a national security concern and should not be restricted. "I don't think that that's the way to compete with China, to try to slow them down," Bourla said. It is irrelevant whether new medicines are developed in China or the US, he said. "The important thing is to have a new medicine, and I don't see any national security concerns for something like that." The rules could allow for billions of dollars of deals to help fill US company drug pipelines and provide capital to Chinese firms. Outside licensing deals in Chinese biotech were worth $115 billion last year, according to research firm GlobalData. Almost half of US deals to bring in licensed drugs from abroad in 2025 were with Chinese companies, according to GlobalData, a trend that has continued into 2026. Bristol Myers Squibb this year signed a partnership with Jiangsu Hengrui Pharma worth up to $15.2 billion, while Pfizer announced an up to $10.5 billion collaboration with Innovent Biologics covering 12 oncology programs. Chinese President Xi Jinping is due to meet with Trump in the US next week. It is unlikely that Treasury will unveil any new rules about investment in pharmaceuticals ahead of the meeting, the three sources and a fourth who was also briefed on the process said. The content of the rules under consideration has not been previously reported. Treasury and White House officials declined to comment. Some lawmakers and smaller drugmakers are not on board with the approach, seeing such investment as a national-security risk that would undercut America's lead role in developing medicines. Some midsize and smaller biotech companies, which often rely on licensing deals with US big pharma, have advocated for the opposite: restrictions that could make Chinese licensing deals more difficult to consummate. Jason Kelly, CEO of Ginkgo Bioworks, which helps biotech companies with their laboratory work, has met with Treasury officials to argue that the US and European pharmaceutical industry will suffer in the long term if current outbound investment to China continues apace. Lawmakers including Republican Representative John Moolenaar, who chairs the House Select Committee on the Chinese Communist Party, and Democrat Debbie Dingell — both of Michigan — have expressed a similar view. Moolenaar has asked Treasury to use the COINS Act, a national security law passed in 2025 aimed at restricting outbound investment, to crack down on pharmaceutical transactions even though the industry was not named in it. The two lawmakers are co-sponsoring a bill proposing tighter Treasury regulation of biotechnology-related investments, licensing agreements and joint ventures involving Chinese companies, not for traditional security reasons but to keep China from dominating biotechnology innovation. The US is working on rules for pharmaceutical companies investing in China that would likely preserve their ability to strike most licensing deals for Chinese drugs, according to three people who have been briefed on the process. The rules — being drafted by the US Treasury Department — are likely to allow US pharmaceutical companies to invest in promising new drugs being developed by Chinese companies as long as they are not related to pathogens or biotechnology that could be weaponized, the sources said. That would mark a departure from the Trump administration's tightening of business with China for other industries under new national security legislation, and would be looser than restrictions sought by some lawmakers.

US weighs allowing most pharma licensing deals with China, sources say

Pharma companies oppose broad curbs

Major deal activity underscores the stakes

Lawmakers and smaller biotechs seek tighter scrutiny

Draft rules would preserve most pharma licensing deals

Related News

Americas Gold and Silver reports new Galena vein discovery grading 1,062 g/t silver over 1.3 meters

Yeti Holdings, Inc. <YETI.N>: Stifel raises to Buy from Hold; raises target price to $50 from $45

Natera says lung cancer MRD study links Signatera results to 3-year recurrence-free survival in 1,129 patients

Enterprise Financial Services Corp <EFSC.O>: Stephens initiates coverage with equal weight rating; target price $70

Eightco reports USD 380 million treasury assets including USD 90 million OpenAI stake, 301,971,219 WLD, 16,278 ETH